KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medpace Holdings (MEDP) Cash & Equivalents (2016 - 2026)

Medpace Holdings filings provide 12 years of Cash & Equivalents readings, the most recent being $652.7 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 47.85% to $652.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $652.7 million, a 47.85% increase, with the full-year FY2025 number at $497.0 million, down 25.75% from a year prior.
  • Cash & Equivalents hit $652.7 million in Q1 2026 for Medpace Holdings, up from $497.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $669.4 million in Q4 2024 to a low of $28.3 million in Q4 2022.
  • Median Cash & Equivalents over the past 5 years was $245.4 million (2023), compared with a mean of $281.1 million.
  • Biggest five-year swings in Cash & Equivalents: plummeted 93.87% in 2022 and later soared 1205.37% in 2024.
  • Medpace Holdings' Cash & Equivalents stood at $28.3 million in 2022, then soared by 768.38% to $245.4 million in 2023, then soared by 172.74% to $669.4 million in 2024, then fell by 25.75% to $497.0 million in 2025, then surged by 31.31% to $652.7 million in 2026.
  • The last three reported values for Cash & Equivalents were $652.7 million (Q1 2026), $497.0 million (Q4 2025), and $285.4 million (Q3 2025) per Business Quant data.